The pharmaceutical company has launched 20 drugs in the past decade to treat diseases from arthritis and psoriasis to diabetes and cancer. In recent months, Lilly has overtaken every competitor to become the most valuable drugmaker in the world.
Read More
Shares in the animal health care company have lost more than two-thirds of their value in the past 18 months, but Elanco says a bevy of new products in its pipeline will prove an era of strong growth is yet to come.
Read More
Elanco Animal Health last week released what CEO Jeff Simmons called its best quarterly earnings since its 2018 spinoff from Eli Lilly and Co.
For Elevance Health and other big insurers, 2024 devolved into something of an annus horribilis over the year’s final weeks. And 2025 holds more challenges but also an opportunity for a rebound.
After a stunning 703% run-up in price over the past five years, shares of Eli Lilly and Co. have been on a roller-coaster ride since September.
After a tough 2023, most publicly traded banks in the Hoosier state have seen at least a partial rebound in their stock prices this year.
The spotlight is turning to Indianapolis-based Eli Lilly and Co. as the next possible member of the so-called “Trillion-Dollar Club,” based on the drugmaker’s climbing stock price and swelling demand for its treatments for diabetes, obesity and other diseases.
In the past 52 weeks, shares have set new records almost every week, due to investor eagerness over the company’s new drugs for obesity and diabetes, two health conditions that plague America, along with other drugs in the pipeline.
In recent weeks, the Indianapolis-based philanthropy has been unveiling a flurry of gifts at the $100 million level or higher.
Most of Indiana’s 14 publicly traded banks have seen a significant drop in stock prices at some point this year, in some cases falling more than 50% from their Jan. 3 prices, the first trading day of the year.
The West Lafayette-based pharmaceutical testing company has seen its stock price soar—and later plunge—following its announcement last fall that it planned to acquire Indianapolis-based Envigo RMS LLC, which breeds and sells animals used in lab testing.
At the close of trading June 24, Bloomberg’s Indiana Index was trading at $375.30, up 0.55% from the beginning of the year. The S&P 500 was down 18.45% and the tech-heavy Nasdaq was down 26.59%.
Shares of the Greenfield-based maker of animal feeds and vaccines dove after the firm warned that it’s facing inflationary pressures, increased logistics costs and other headwinds.
The past year has been awful for Carmel-based Invesque, as COVID-19 hurt the full gamut of its health care real estate portfolio, from nursing homes and office buildings to memory-care and assisted-living centers.
If you follow the daily drumbeat of news emanating out of Lilly Corporate Center, you might not grasp how phenomenally well the company is poised to perform in the coming years.
A nontraditional way to take companies public is booming on Wall Street, leading to an unprecedented explosion of deals.
Biglari Holdings’ Sardar Biglari is pushing for reforms at Cracker Barrel Old Country Store even as Biglari restaurant Steak n Shake teeters.
Many of Indiana’s 54 public companies have withdrawn their earnings guidance for the year, even as executives emphasize their belief that they are positioned well for the long term.
Investors in Angie’s List Inc. appeared to have hit the jackpot two years ago after the company merged with rival HomeAdvisor. Unfortunately, that love affair is officially over.
The company’s shares—like those of many in retail real estate—are out of favor, as investors wring their hands over retail bankruptcies and the long-term impact of e-commerce.
More than two dozen of the state’s 51 public companies posting double-digit percentage gains in the first quarter.
The Indianapolis-based pharmaceutical giant on Wednesday tempered expectations for its earnings in 2019 after a promising cancer drug failed to pan out and the firm prepared for big acquisition.
